主权项 |
1. A method of identifying one or more candidate treatment for an ovarian cancer in a subject in need thereof, comprising:
(a) determining a molecular profile for one or more sample from the subject on a panel of gene or gene products, wherein the molecular profile comprises the results of assessing the panel of gene or gene products by:
performing immunohistochemistry (IHC) analysis on the one or more sample from the subject on one or more of: AR, BCRP, CAV-1, CD20, CD52, CK 5/6, CK14, CK17, c-kit, CMET, COX-2, Cyclin D1, E-Cad, EGFR, ER, ERCC1, HER-2, IGF1R, Ki67, MGMT, MRP1, P53, p95, PDGFR, PGP, PR, PTEN, RRM1, SPARC, TLE3, TOPO1, TOPO2A, TS and TUBB3;performing gene expression analysis on the one or more sample on one or more of: ABCC1, ABCG2, ADA, AR, ASNS, BCL2, BIRC5, BRCA1, BRCA2, CD33, CD52, CDA, CES2, cKit, c-MYC, DCK, DHFR, DNMT1, DNMT3A, DNMT3B, ECGF1, EGFR, EPHA2, ERCC1, ERCC3, ESR1-, FLT1, FOLR2, FYN, GART, GNRH1, GSTP1, HCK, HDAC1, HER2/ERBB2, HIF1A, HSP90, IGFBP3, IGFBP4, IGFBP5, IL2RA, KDR, LCK, LYN, MET, MGMT, MLH1, MS4A1, MSH2, NFKB1, NFKB2, NFKBIA, OGFR, PARP1, PDGFC, PDGFRa, PDGFRA, PDGFRB, PGP, PGR, POLA1, PTEN, PTGS2, RAF1, RARA, RRM1, RRM2, RRM2B, RXRB, RXRG, SIK2, SRC, SSTR1, SSTR2, SSTR3, SSTR4, SSTR5, SPARC, TK1, TNF, TOP2B, TOP2A, TOPO1, TXNRD1, TYMS, VDR, VEGFA, VHL, YES1, and ZAP70;performing fluorescent in-situ hybridization (FISH) analysis on the one or more sample on at least one of: ALK, cMET, c-MYC, EGFR, HER-2, PIK3CA, and TOPO2A; andperforming DNA sequence analysis or PCR on the one or more sample on at least one of: BRAF, c-kit, EGFR, KRAS, NRAS, and PIK3CA; (b) comparing the molecular profile of the subject to a molecular profile of a reference to identify which of the members of the panel are differentially expressed, amplified or mutated as compared to the reference; (c) accessing a computer database to identify one or more treatment that is associated with one or more members of the panel that are differentially expressed, amplified or mutated as compared to the reference; and (d) providing a computer generated report that identifies the at least one drug therapy identified in step c), thereby identifying the one or more candidate treatment. |